KD Pharma strengthens its technology platform by acquiring UK manufacturing site

3 June 2019

Acquisition allows KD Pharma to further expand its leading position in the omega-3 pharmaceutical market

KD Pharma Group SA announced that it has acquired a manufacturing site in Seal Sands, UK. The KD Pharma UK LTD entity will expand KD Pharma’s capacity for manufacturing omega-3-based intermediates used in producing active pharmaceutical ingredients (APIs). The site was previously used for manufacturing omega-3 products.

“This acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,” said Oscar Groet, KD Pharma Group’s CEO. “The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids,” he concluded.

KD Pharma Group strives to be the leading manufacturer in the rapidly growing omega-3 API market. The UK acquisition will enable it to meet market demand for the highest quality APIs in response to new product approvals, label expansions, and supportive clinical research. The company says the site will be brought online this year and operated alongside KD Pharma Group’s other manufacturing sites in Bexbach, Germany; Brattvag, Norway; and Miami, United States.

Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.